Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
The global recombinant proteins market size is projected to reach USD 3.2 billion by 2028 from USD 2.2 billion in 2023, at a CAGR of 7.2% during the forecast period. Factors such as rising demand for biologics & biosimilars due to patent expiry, increasing prevalence of chronic diseases, increased government support for life sciences research & development and growing preference for personalized medicine..
“The growth factors and chemokines segment segment held the dominant share in the recombinant proteins market”
Based on product, the global recombinant proteins market is segmented into growth factors and chemokines, kinase proteins, membrane proteins, immune response proteins, structural proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. The growth factors and chemokines segment is further segmented into interferons, interleukins and other growth factor & chemokines. The growth factors and chemokines segment is anticipated to grow at significant CAGR due to their application in cell culture, protein expression, and modulation of cellular responses.
“Drug discovery & development segment accounted for the largest share of the application segment in 2022.”
Based on application, the recombinant proteins market is segmented into, drug discovery and development, biopharmaceutical production, research, diagnostics, and other applications. In 2022, the drug discovery and development segment accounted for the largest share of the recombinant proteins market. The segment held the largest share in the market due to application of recombinant proteins in developing biopharmaceuticals and understanding the functions of potential drug targets.
“Asia Pacific region is likely to grow at a faster pace in the recombinant proteins market.”
The recombinant proteins market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by increasing demand for protein based drugs, rising government funding for recombinant proteins production and development of biotechnology-based drugs.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the recombinant proteins market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall recombinant proteins market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“The growth factors and chemokines segment segment held the dominant share in the recombinant proteins market”
Based on product, the global recombinant proteins market is segmented into growth factors and chemokines, kinase proteins, membrane proteins, immune response proteins, structural proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. The growth factors and chemokines segment is further segmented into interferons, interleukins and other growth factor & chemokines. The growth factors and chemokines segment is anticipated to grow at significant CAGR due to their application in cell culture, protein expression, and modulation of cellular responses.
“Drug discovery & development segment accounted for the largest share of the application segment in 2022.”
Based on application, the recombinant proteins market is segmented into, drug discovery and development, biopharmaceutical production, research, diagnostics, and other applications. In 2022, the drug discovery and development segment accounted for the largest share of the recombinant proteins market. The segment held the largest share in the market due to application of recombinant proteins in developing biopharmaceuticals and understanding the functions of potential drug targets.
“Asia Pacific region is likely to grow at a faster pace in the recombinant proteins market.”
The recombinant proteins market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by increasing demand for protein based drugs, rising government funding for recombinant proteins production and development of biotechnology-based drugs.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70%, and Demand Side - 30%
- By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
- By Region: North America: 40%, Europe: 25%, Asia Pacific: 20%, Latin America: 10%, and the Middle East and Africa: 5%
- Bio-Techne (US)
- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- Abcam plc (UK)
- Abnova Corporation (Taiwan)
- Biolegend Inc (US)
- Bio-Rad Laboratories Inc. (US)
- BPS Bioscienc Inc (US)
- Enzo Biochem, Inc. (US)
- GenScript (China)
- Miltenyi Biotec B.V. & Co. KG (Germany)
- Proteintech Group, Inc. (US)
- Sino Biological Inc. (China)
- ACROBiosystems Group (US)
- Aviva Systems Biology Corporation (US)
- Sartorius CellGenix GmbH (Germany)
- Icosagen (Estonia)
- Neuromics (US)
- ProSpec-Tany Technogene Ltd. (Israel)
- ProteoGenix S.A.S (France)
- RayBiotech Inc (US)
- Lauraus Bio (India)
- Stemcell Technologies (Canada)
- StressMarq Biosciences Inc. (Canada)
- United States Biological (US)
This report provides a detailed picture of the recombinant proteins market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall recombinant proteins market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising incidence of chronic diseases, unleashing innovation in biologics and biosimilars with patent expiry, increasing government support for R&D in life sciences, growing preference for personalized medicine), restraints (high production costs, stringent regulatory approval processes), opportunities (advancements in gene editing technologies, high growth potential of emerging markets, emergence of novel expression systems) and challenges (challenges associated with delivery systems) are influencing the growth of recombinant proteins market.
- Product Development/Innovation: Detailed insights on newly launched products of the recombinant proteins market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the recombinant proteins market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the recombinant proteins market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Bio-Techne (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Abnova Corporation (Taiwan), Biolegend Inc (US), Bio-Rad Laboratories Inc. (US), BPS Bioscienc Inc (US), Enzo Biochem Inc. (US) and GenScript (China).
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 RECOMBINANT PROTEINS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY SIDE ANALYSIS (2022)
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, APPLICATION, HOST CELL, AND END USER)
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
FIGURE 8 RECOMBINANT PROTEINS MARKET: CAGR PROJECTIONS (2023–2028)
FIGURE 9 RECOMBINANT PROTEINS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024?2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 11 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 12 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 13 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 14 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 15 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2023 VS. 2028 (USD MILLION)
FIGURE 16 RECOMBINANT PROTEINS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RECOMBINANT PROTEINS MARKET
4 PREMIUM INSIGHTS
4.1 RECOMBINANT PROTEINS MARKET OVERVIEW
FIGURE 18 INCREASING GOVERNMENT SUPPORT FOR R&D IN LIFE SCIENCES TO DRIVE MARKET
4.2 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT (2022)
FIGURE 19 GROWTH FACTORS & CHEMOKINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028
FIGURE 20 GROWTH FACTORS & CHEMOKINES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 RECOMBINANT PROTEINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 RECOMBINANT PROTEINS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of chronic diseases
FIGURE 23 NUMBER OF CANCER CASES IN US (2017 - 2022)
5.2.1.2 Increasing demand for biologics and biosimilars due to patent expiry
5.2.1.3 Increasing government support for R&D in life sciences
TABLE 5 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022)
5.2.1.4 Growing preference for personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 High production costs
5.2.2.2 Stringent regulatory approval processes
5.2.3 OPPORTUNITIES
5.2.3.1 Advancements in gene editing technologies
5.2.3.2 High growth potential of emerging markets
5.2.3.3 Emergence of novel expression systems
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with delivery systems
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 24 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR RECOMBINANT PROTEIN MANUFACTURERS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS
TABLE 6 RECOMBINANT PROTEIN PRODUCTS
5.4.2 AVERAGE SELLING PRICE TREND OF RECOMBINANT PROTEINS
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: MANUFACTURING & ASSEMBLY PHASE CONTRIBUTES MAXIMUM VALUE TO VALUE CHAIN OF RECOMBINANT PROTEINS
5.7 ECOSYSTEM MARKET/MAP
FIGURE 26 ECOSYSTEM MARKET/MAP
TABLE 7 RECOMBINANT PROTEINS MARKET: ROLE IN ECOSYSTEM:
5.8 REGULATORY ANALYSIS
TABLE 8 KEY REGULATORY AGENCIES
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 15 RECOMBINANT PROTEINS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 PATENT ANALYSIS
FIGURE 27 PATENT APPLICATIONS FOR RECOMBINANT PROTEINS, DECEMBER 2013–DECEMBER 2023
TABLE 16 RECOMBINANT PROTEINS MARKET: INDICATIVE LIST OF PATENTS
5.11 KEY CONFERENCES AND EVENTS
TABLE 17 DETAILED LIST OF KEY CONFERENCES AND EVENTS (2023–2024)
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RECOMBINANT PROTEINS
5.12.2 BUYING CRITERIA FOR RECOMBINANT PROTEINS
FIGURE 29 KEY BUYING CRITERIA FOR END USERS
6 RECOMBINANT PROTEINS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 18 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 GROWTH FACTORS & CHEMOKINES
TABLE 19 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 21 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, COUNTRY, 2021–2028 (USD MILLION)
6.2.1 INTERFERONS (IFNS)
6.2.1.1 Ability to regulate critical cellular processes across research applications to propel market
TABLE 26 RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 27 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 28 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2 INTERLEUKINS (ILS)
6.2.2.1 Rising focus on personalized therapeutics to drive market
TABLE 32 RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 33 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 ASAI PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.3 OTHER GROWTH FACTORS & CHEMOKINES
TABLE 38 RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 39 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 IMMUNE RESPONSE PROTEINS
6.3.1 HIGH UTILIZATION OF IMMUNE CHECKPOINT PROTEINS IN CANCER IMMUNOTHERAPY TO PROPEL MARKET
TABLE 44 RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 EUROPE: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 STRUCTURAL PROTEINS
6.4.1 ATTACHMENT FACTORS IN CELL CULTURE APPLICATIONS TO DRIVE MARKET
TABLE 50 RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 51 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 MEMBRANE PROTEINS
6.5.1 ESSENTIAL PROCESS REGULATION OF STRUCTURAL CELLS TO SUPPORT MARKET GROWTH
TABLE 56 RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 EUROPE: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.6 KINASE PROTEINS
6.6.1 ACTIVE METABOLIZATION OF LIPIDS AND NUCLEOTIDES TO DRIVE MARKET
TABLE 62 RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 63 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 EUROPE: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 66 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.7 REGULATORY PROTEINS
6.7.1 ABILITY TO MODULATE CELLULAR PROCESSES TO DRIVE MARKET
TABLE 68 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 69 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 EUROPE: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.8 RECOMBINANT METABOLIC ENZYMES
6.8.1 HIGH ADOPTION IN BIOTECHNOLOGICAL APPLICATIONS FOR THERAPEUTIC DEVELOPMENT TO BOOST DEMAND
TABLE 74 RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY REGION, 2021–2028 (USD MILLION)
TABLE 75 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
6.9 ADHESION MOLECULES & RECEPTORS
6.9.1 ENHANCED FACILITATION OF EXTRACELLULAR MATRIX INTERACTIONS TO SUPPORT MARKET GROWTH
TABLE 80 RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 81 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 EUROPE: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
6.10 OTHER RECOMBINANT PROTEINS
TABLE 86 RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 87 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
7 RECOMBINANT PROTEINS MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 92 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
7.2 DRUG DISCOVERY & DEVELOPMENT
TABLE 93 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 94 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)
TABLE 95 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 99 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1 BIOLOGICS
7.2.1.1 High adoption in autoimmune disease & cancer treatment to propel market
TABLE 100 RECOMBINANT PROTEINS MARKET: KEY BIOLOGICS AND INDICATIONS
TABLE 101 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.2 VACCINES
7.2.2.1 Rising incidence of infectious diseases to boost demand
TABLE 107 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 108 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 110 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 111 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.3 CELL & GENE THERAPY
7.2.3.1 Growing focus on CAR-T therapies to propel market
TABLE 113 RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 118 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 RESEARCH
TABLE 119 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 120 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY REGION, 2021–2028 USD MILLION)
TABLE 121 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 122 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 123 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 124 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 125 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
7.3.1 ACADEMIC RESEARCH
7.3.1.1 Wide application in molecular & gene expression studies to propel market
TABLE 126 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 127 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 128 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 129 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 130 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 131 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
7.3.2 BIOTECHNOLOGY RESEARCH
7.3.2.1 Growing focus on bioengineering and genomics to fuel market
TABLE 132 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2021–2028 (USD MILLION)
TABLE 133 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 134 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 136 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 137 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 BIOPHARMACEUTICAL PRODUCTION
7.4.1 INCREASING DEVELOPMENT OF PROTEIN-BASED DRUGS TO SUPPORT MARKET GROWTH
TABLE 138 RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2021–2028 (USD MILLION)
TABLE 139 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 141 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 142 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 143 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 DIAGNOSTICS
7.5.1 GROWING FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
TABLE 144 RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 145 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 146 EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 147 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 148 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 149 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 OTHER APPLICATIONS
TABLE 150 RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 151 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 152 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 153 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 154 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 155 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8 RECOMBINANT PROTEINS MARKET, BY HOST CELL
8.1 INTRODUCTION
TABLE 156 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
8.2 MAMMALIAN SYSTEMS
8.2.1 HIGH UPTAKE IN BIOTECHNOLOGY APPLICATIONS TO PROPEL MARKET
TABLE 157 RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
TABLE 158 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 159 EUROPE: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 160 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 161 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 162 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 INSECT CELLS
8.3.1 COST-EFFICIENT AND HIGH-YIELD CHARACTERISTICS TO DRIVE MARKET
TABLE 163 RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 164 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 165 EUROPE: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 166 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 167 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 168 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 YEAST & FUNGI
8.4.1 NEW APPLICATIONS IN VACCINE DEVELOPMENT AND DIABETES TREATMENT TO BOOST DEMAND
TABLE 169 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY REGION, 2021–2028 (USD MILLION)
TABLE 170 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 171 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 172 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 173 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 174 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 BACTERIAL CELLS
8.5.1 SIMPLIFIED GENETIC MANIPULATION AND SCALABILITY ADVANTAGES TO DRIVE MARKET
TABLE 175 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 176 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 177 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 178 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 179 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 180 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
8.6 OTHER HOST CELLS
TABLE 181 RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 182 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 183 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 184 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 185 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 186 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
9 RECOMBINANT PROTEINS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 187 RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 RISING DEVELOPMENT OF GENE THERAPIES AND VACCINES TO PROPEL MARKET
TABLE 188 RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 189 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 190 EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 191 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 192 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 193 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 BIOTECHNOLOGY COMPANIES
9.3.1 RISING NUMBER OF PROTEIN-BASED RESEARCH PROJECTS TO BOOST DEMAND
TABLE 194 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 195 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 196 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 197 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 198 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 199 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 FAVORABLE GOVERNMENT INVESTMENTS TO PROPEL MARKET
TABLE 200 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
TABLE 201 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 202 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 203 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 204 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 205 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 RISING OUTSOURCING OF CLINICAL TRIAL SERVICES TO SUPPORT MARKET GROWTH
TABLE 206 RECOMBINANT PROTEINS MARKET FOR CROS, BY REGION, 2021–2028 (USD MILLION)
TABLE 207 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 208 EUROPE: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 209 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 210 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 211 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
9.6 OTHER END USERS
TABLE 212 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 213 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 214 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 215 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 216 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 USD MILLION)
TABLE 217 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
10 RECOMBINANT PROTEINS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 218 RECOMBINANT PROTEINS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: RECOMBINANT PROTEINS MARKET SNAPSHOT
TABLE 219 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 220 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 221 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 222 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 223 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 224 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 225 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 USD MILLION)
TABLE 226 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 Rising investments in life sciences research to drive market
TABLE 227 US: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 228 US: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 229 US: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 230 US: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 231 US: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 232 US: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 233 US: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 High incidence of cancer and favorable healthcare investments to drive market
TABLE 234 CANADA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 235 CANADA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 236 CANADA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 237 CANADA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 238 CANADA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 239 CANADA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 240 CANADA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
TABLE 241 EUROPE: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 242 EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 243 EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 244 EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 245 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 246 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 247 EUROPE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 248 EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Growing focus on biotech clusters to drive market
TABLE 249 GERMANY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 250 GERMANY: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 251 GERMANY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 252 GERMANY: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 253 GERMANY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 254 GERMANY: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 255 GERMANY: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Rising demand for biologics and biosimilars to propel market
TABLE 256 UK: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 257 UK: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 258 UK: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 259 UK: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 260 UK: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 261 UK: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 262 UK: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising establishment of biopharmaceutical production facilities to boost demand
TABLE 263 FRANCE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 264 FRANCE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 265 FRANCE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 266 FRANCE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 267 FRANCE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 268 FRANCE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 269 FRANCE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Growth in proteomics and genomics research to drive market
TABLE 270 ITALY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 271 ITALY: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 272 ITALY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 273 ITALY: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 274 ITALY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 275 ITALY: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 276 ITALY: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Rising establishment of pharmaceutical production facilities to drive market
TABLE 277 SPAIN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 278 SPAIN: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 279 SPAIN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 280 SPAIN: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 281 SPAIN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 282 SPAIN: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 283 SPAIN: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 284 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 285 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 286 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 287 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 288 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 289 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 290 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET SNAPSHOT
TABLE 291 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 292 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 293 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 294 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 295 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH APPLICATION, BY TYPE, 2021–2028 (USD MILLION)
TABLE 296 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2021–2028 (USD MILLION)
TABLE 297 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 298 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Expansion of R&D infrastructure to support market growth
TABLE 299 CHINA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 300 CHINA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 301 CHINA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 302 CHINA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 303 CHINA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 304 CHINA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 305 CHINA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Growth in pharmaceutical industry to propel market
TABLE 306 JAPAN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 307 JAPAN: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 308 JAPAN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 309 JAPAN: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 310 JAPAN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 311 JAPAN: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 312 JAPAN: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Rising demand for drug discovery & development to propel market
TABLE 313 INDIA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 314 INDIA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 315 INDIA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 316 INDIA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 317 INDIA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 318 INDIA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 319 INDIA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Rising incidence of infectious diseases to drive market
TABLE 320 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 321 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 322 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 323 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 324 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 325 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 326 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 327 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 328 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 329 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 330 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 331 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 332 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 333 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
TABLE 334 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 335 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 336 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 337 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 338 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 339 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 340 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 341 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 Rising incidence of chronic diseases to drive market
TABLE 342 BRAZIL: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 343 BRAZIL: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 344 BRAZIL: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 345 BRAZIL: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 346 BRAZIL: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 347 BRAZIL: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 348 BRAZIL: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 349 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 350 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 351 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 352 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 353 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 354 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 355 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6 MIDDLE EAST
TABLE 356 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 357 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 358 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 359 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 360 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 361 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 362 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 363 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6.1 MIDDLE EAST: RECESSION IMPACT
10.6.2 GCC COUNTRIES
10.6.2.1 Rising government investments in healthcare to support market growth
TABLE 364 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 365 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 366 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 367 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 368 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 369 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 370 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6.3 REST OF THE MIDDLE EAST
TABLE 371 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 372 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 373 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 374 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 375 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 376 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 377 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.7 AFRICA
10.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
TABLE 378 AFRICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 379 AFRICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 380 AFRICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 381 AFRICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 382 AFRICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 383 AFRICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 384 AFRICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES
FIGURE 32 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
11.3 REVENUE SHARE ANALYSIS
FIGURE 33 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020?2022)
11.4 MARKET SHARE ANALYSIS
FIGURE 34 RECOMBINANT PROTEINS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 385 RECOMBINANT PROTEINS MARKET: INTENSITY OF COMPETITIVE RIVALRY
11.5 COMPANY EVALUATION MATRIX
FIGURE 35 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPETITIVE BENCHMARKING
11.5.5.1 Product footprint (15 companies)
TABLE 386 RECOMBINANT PROTEINS MARKET: COMPANY PRODUCT FOOTPRINT
11.5.5.2 Regional footprint
TABLE 387 RECOMBINANT PROTEINS MARKET: REGIONAL FOOTPRINT ANALYSIS
11.6 START-UP/SME EVALUATION MATRIX
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 36 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022)
11.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES
TABLE 388 RECOMBINANT PROTEINS MARKET: PRODUCT FOOTPRINT
TABLE 389 RECOMBINANT PROTEINS MARKET: REGIONAL FOOTPRINT
11.7 COMPETITIVE SCENARIO
11.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 390 RECOMBINANT PROTEINS MARKET: PRODUCT LAUNCHES & APPROVALS, (JANUARY 2021–SEPTEMBER 2023)
11.7.2 DEALS
TABLE 391 RECOMBINANT PROTEINS MARKET: DEALS (JANUARY 2021?SEPTEMBER 2023)
11.7.3 OTHER DEVELOPMENTS
TABLE 392 RECOMBINANT PROTEINS MARKET: OTHER DEVELOPMENTS (JANUARY 2021?SEPTEMBER 2023)
12 COMPANY PROFILES
(Business overview, Products offered, Recent developments & MnM View)*
12.1 KEY PLAYERS
12.1.1 BIO-TECHNE
TABLE 393 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 37 BIO?TECHNE: COMPANY SNAPSHOT (2022)
TABLE 394 BIO?TECHNE: PRODUCTS OFFERED
TABLE 395 BIO-TECHNE: DEALS
TABLE 396 BIO-TECHNE: OTHER DEVELOPMENTS
12.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 397 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
TABLE 398 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 399 THERMO FISHER SCIENTIFIC INC: DEALS
12.1.3 MERCK KGAA
TABLE 400 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2022)
TABLE 401 MERCK KGAA: PRODUCTS OFFERED
TABLE 402 MERCK KGAA: DEALS
TABLE 403 MERCK KGAA: OTHER DEVELOPMENTS
12.1.4 ABCAM PLC
TABLE 404 ABCAM PLC: BUSINESS OVERVIEW
FIGURE 40 ABCAM PLC: COMPANY SNAPSHOT (2022)
TABLE 405 ABCAM PLC: PRODUCTS OFFERED
TABLE 406 ABCAM PLC: DEALS
TABLE 407 ABCAM PLC: OTHER DEVELOPMENTS
12.1.5 ABNOVA CORPORATION
TABLE 408 ABNOVA CORPORATION: BUSINESS OVERVIEW
TABLE 409 ABNOVA CORPORATION: PRODUCTS OFFERED
12.1.6 BIOLEGEND, INC
TABLE 410 BIOLEGEND INC: BUSINESS OVERVIEW
TABLE 411 BIOLEGEND INC: PRODUCTS OFFERED
12.1.7 BIO-RAD LABORATORIES, INC.
TABLE 412 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 41 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
TABLE 413 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
12.1.8 BPS BIOSCIENCE, INC.
TABLE 414 BPS BIOSCIENCE, INC.: BUSINESS OVERVIEW
TABLE 415 BPS BIOSCIENCE, INC.: PRODUCTS OFFERED
12.1.9 ENZO LIFE SCIENCES, INC. (SUBSIDIARY OF ENZO BIOCHEM, INC.)
TABLE 416 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
FIGURE 42 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022)
TABLE 417 ENZO BIOCHEM, INC.: PRODUCTS OFFERED
TABLE 418 ENZO BIOCHEM, INC.: OTHER DEVELOPMENTS
12.1.10 GENSCRIPT
TABLE 419 GENSCRIPT: BUSINESS OVERVIEW
FIGURE 43 GENSCRIPT: COMPANY SNAPSHOT (2022)
TABLE 420 GENSCRIPT: PRODUCTS OFFERED
12.1.11 MILTENYI BIOTEC B.V. & CO. KG
TABLE 421 MILTENYI BIOTEC B.V. & CO. KG: BUSINESS OVERVIEW
TABLE 422 MILTENYI BIOTEC B.V. & CO. KG: PRODUCTS OFFERED
TABLE 423 MILTENYI BIOTEC B.V. & CO. KG: PRODUCT LAUNCHES
12.1.12 PROTEINTECH GROUP, INC.
TABLE 424 PROTEINTECH GROUP, INC.: BUSINESS OVERVIEW
TABLE 425 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED
TABLE 426 PROTEINTECH GROUP, INC.: DEALS
TABLE 427 PROTEINTECH GROUP, INC.: OTHER DEVELOPMENTS
12.1.13 SINO BIOLOGICAL, INC.
TABLE 428 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
TABLE 429 SINO BIOLOGICAL, INC.: PRODUCTS OFFERED
TABLE 430 SINO BIOLOGICAL, INC.: PRODUCT LAUNCHES
TABLE 431 SINO BIOLOGICAL, INC.: DEALS
TABLE 432 SINO BIOLOGICAL, INC.: OTHER DEVELOPMENTS
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 ACROBIOSYSTEMS GROUP
12.2.2 AVIVA SYSTEMS BIOLOGY CORPORATION
12.2.3 SARTORIUS CELLGENIX GMBH
12.2.4 ICOSAGEN
12.2.5 NEUROMICS
12.2.6 PROSPEC-TANY TECHNOGENE LTD.
12.2.7 PROTEOGENIX S.A.S
12.2.8 RAYBIOTECH, INC.
12.2.9 LAURUS BIO
12.2.10 STEMCELL TECHNOLOGIES
12.2.11 STRESSMARQ BIOSCIENCES INC.
12.2.12 UNITED STATES BIOLOGICAL
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 RECOMBINANT PROTEINS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY SIDE ANALYSIS (2022)
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)
2.2.1 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, APPLICATION, HOST CELL, AND END USER)
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
FIGURE 8 RECOMBINANT PROTEINS MARKET: CAGR PROJECTIONS (2023–2028)
FIGURE 9 RECOMBINANT PROTEINS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024?2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 11 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 12 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 13 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 14 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 15 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2023 VS. 2028 (USD MILLION)
FIGURE 16 RECOMBINANT PROTEINS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RECOMBINANT PROTEINS MARKET
4 PREMIUM INSIGHTS
4.1 RECOMBINANT PROTEINS MARKET OVERVIEW
FIGURE 18 INCREASING GOVERNMENT SUPPORT FOR R&D IN LIFE SCIENCES TO DRIVE MARKET
4.2 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT (2022)
FIGURE 19 GROWTH FACTORS & CHEMOKINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028
FIGURE 20 GROWTH FACTORS & CHEMOKINES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 RECOMBINANT PROTEINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 RECOMBINANT PROTEINS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of chronic diseases
FIGURE 23 NUMBER OF CANCER CASES IN US (2017 - 2022)
5.2.1.2 Increasing demand for biologics and biosimilars due to patent expiry
5.2.1.3 Increasing government support for R&D in life sciences
TABLE 5 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022)
5.2.1.4 Growing preference for personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 High production costs
5.2.2.2 Stringent regulatory approval processes
5.2.3 OPPORTUNITIES
5.2.3.1 Advancements in gene editing technologies
5.2.3.2 High growth potential of emerging markets
5.2.3.3 Emergence of novel expression systems
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with delivery systems
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 24 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR RECOMBINANT PROTEIN MANUFACTURERS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS
TABLE 6 RECOMBINANT PROTEIN PRODUCTS
5.4.2 AVERAGE SELLING PRICE TREND OF RECOMBINANT PROTEINS
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: MANUFACTURING & ASSEMBLY PHASE CONTRIBUTES MAXIMUM VALUE TO VALUE CHAIN OF RECOMBINANT PROTEINS
5.7 ECOSYSTEM MARKET/MAP
FIGURE 26 ECOSYSTEM MARKET/MAP
TABLE 7 RECOMBINANT PROTEINS MARKET: ROLE IN ECOSYSTEM:
5.8 REGULATORY ANALYSIS
TABLE 8 KEY REGULATORY AGENCIES
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 15 RECOMBINANT PROTEINS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 PATENT ANALYSIS
FIGURE 27 PATENT APPLICATIONS FOR RECOMBINANT PROTEINS, DECEMBER 2013–DECEMBER 2023
TABLE 16 RECOMBINANT PROTEINS MARKET: INDICATIVE LIST OF PATENTS
5.11 KEY CONFERENCES AND EVENTS
TABLE 17 DETAILED LIST OF KEY CONFERENCES AND EVENTS (2023–2024)
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RECOMBINANT PROTEINS
5.12.2 BUYING CRITERIA FOR RECOMBINANT PROTEINS
FIGURE 29 KEY BUYING CRITERIA FOR END USERS
6 RECOMBINANT PROTEINS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 18 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 GROWTH FACTORS & CHEMOKINES
TABLE 19 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 21 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 23 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, COUNTRY, 2021–2028 (USD MILLION)
6.2.1 INTERFERONS (IFNS)
6.2.1.1 Ability to regulate critical cellular processes across research applications to propel market
TABLE 26 RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 27 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 28 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2 INTERLEUKINS (ILS)
6.2.2.1 Rising focus on personalized therapeutics to drive market
TABLE 32 RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 33 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 35 ASAI PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 36 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.3 OTHER GROWTH FACTORS & CHEMOKINES
TABLE 38 RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 39 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 41 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 IMMUNE RESPONSE PROTEINS
6.3.1 HIGH UTILIZATION OF IMMUNE CHECKPOINT PROTEINS IN CANCER IMMUNOTHERAPY TO PROPEL MARKET
TABLE 44 RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 EUROPE: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 48 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 49 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 STRUCTURAL PROTEINS
6.4.1 ATTACHMENT FACTORS IN CELL CULTURE APPLICATIONS TO DRIVE MARKET
TABLE 50 RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 51 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 EUROPE: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 MEMBRANE PROTEINS
6.5.1 ESSENTIAL PROCESS REGULATION OF STRUCTURAL CELLS TO SUPPORT MARKET GROWTH
TABLE 56 RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 EUROPE: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 60 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 61 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.6 KINASE PROTEINS
6.6.1 ACTIVE METABOLIZATION OF LIPIDS AND NUCLEOTIDES TO DRIVE MARKET
TABLE 62 RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 63 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 EUROPE: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 66 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.7 REGULATORY PROTEINS
6.7.1 ABILITY TO MODULATE CELLULAR PROCESSES TO DRIVE MARKET
TABLE 68 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 69 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 70 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 EUROPE: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 73 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
6.8 RECOMBINANT METABOLIC ENZYMES
6.8.1 HIGH ADOPTION IN BIOTECHNOLOGICAL APPLICATIONS FOR THERAPEUTIC DEVELOPMENT TO BOOST DEMAND
TABLE 74 RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY REGION, 2021–2028 (USD MILLION)
TABLE 75 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
6.9 ADHESION MOLECULES & RECEPTORS
6.9.1 ENHANCED FACILITATION OF EXTRACELLULAR MATRIX INTERACTIONS TO SUPPORT MARKET GROWTH
TABLE 80 RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY REGION, 2021–2028 (USD MILLION)
TABLE 81 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 EUROPE: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 85 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION)
6.10 OTHER RECOMBINANT PROTEINS
TABLE 86 RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2021–2028 (USD MILLION)
TABLE 87 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION)
7 RECOMBINANT PROTEINS MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 92 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
7.2 DRUG DISCOVERY & DEVELOPMENT
TABLE 93 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 94 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)
TABLE 95 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 98 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 99 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.1 BIOLOGICS
7.2.1.1 High adoption in autoimmune disease & cancer treatment to propel market
TABLE 100 RECOMBINANT PROTEINS MARKET: KEY BIOLOGICS AND INDICATIONS
TABLE 101 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 105 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.2 VACCINES
7.2.2.1 Rising incidence of infectious diseases to boost demand
TABLE 107 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
TABLE 108 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 110 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 111 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
7.2.3 CELL & GENE THERAPY
7.2.3.1 Growing focus on CAR-T therapies to propel market
TABLE 113 RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 117 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 118 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 RESEARCH
TABLE 119 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 120 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY REGION, 2021–2028 USD MILLION)
TABLE 121 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 122 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 123 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 124 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 125 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
7.3.1 ACADEMIC RESEARCH
7.3.1.1 Wide application in molecular & gene expression studies to propel market
TABLE 126 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 127 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 128 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 129 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 130 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 131 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
7.3.2 BIOTECHNOLOGY RESEARCH
7.3.2.1 Growing focus on bioengineering and genomics to fuel market
TABLE 132 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2021–2028 (USD MILLION)
TABLE 133 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 134 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 136 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 137 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 BIOPHARMACEUTICAL PRODUCTION
7.4.1 INCREASING DEVELOPMENT OF PROTEIN-BASED DRUGS TO SUPPORT MARKET GROWTH
TABLE 138 RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2021–2028 (USD MILLION)
TABLE 139 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 141 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 142 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 143 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 DIAGNOSTICS
7.5.1 GROWING FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
TABLE 144 RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
TABLE 145 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 146 EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 147 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 148 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 149 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 OTHER APPLICATIONS
TABLE 150 RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 151 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 152 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 153 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 154 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 155 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8 RECOMBINANT PROTEINS MARKET, BY HOST CELL
8.1 INTRODUCTION
TABLE 156 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
8.2 MAMMALIAN SYSTEMS
8.2.1 HIGH UPTAKE IN BIOTECHNOLOGY APPLICATIONS TO PROPEL MARKET
TABLE 157 RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
TABLE 158 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 159 EUROPE: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 160 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 161 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 162 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 INSECT CELLS
8.3.1 COST-EFFICIENT AND HIGH-YIELD CHARACTERISTICS TO DRIVE MARKET
TABLE 163 RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 164 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 165 EUROPE: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 166 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 167 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 168 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 YEAST & FUNGI
8.4.1 NEW APPLICATIONS IN VACCINE DEVELOPMENT AND DIABETES TREATMENT TO BOOST DEMAND
TABLE 169 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY REGION, 2021–2028 (USD MILLION)
TABLE 170 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 171 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 172 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 173 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 174 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 BACTERIAL CELLS
8.5.1 SIMPLIFIED GENETIC MANIPULATION AND SCALABILITY ADVANTAGES TO DRIVE MARKET
TABLE 175 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 176 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 177 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 178 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 179 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 180 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
8.6 OTHER HOST CELLS
TABLE 181 RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY REGION, 2021–2028 (USD MILLION)
TABLE 182 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 183 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 184 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 185 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 186 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
9 RECOMBINANT PROTEINS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 187 RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.2.1 RISING DEVELOPMENT OF GENE THERAPIES AND VACCINES TO PROPEL MARKET
TABLE 188 RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 189 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 190 EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 191 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 192 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 193 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 BIOTECHNOLOGY COMPANIES
9.3.1 RISING NUMBER OF PROTEIN-BASED RESEARCH PROJECTS TO BOOST DEMAND
TABLE 194 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 195 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 196 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 197 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 198 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 199 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 FAVORABLE GOVERNMENT INVESTMENTS TO PROPEL MARKET
TABLE 200 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
TABLE 201 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 202 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 203 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 204 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 205 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 RISING OUTSOURCING OF CLINICAL TRIAL SERVICES TO SUPPORT MARKET GROWTH
TABLE 206 RECOMBINANT PROTEINS MARKET FOR CROS, BY REGION, 2021–2028 (USD MILLION)
TABLE 207 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 208 EUROPE: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 209 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 210 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 211 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION)
9.6 OTHER END USERS
TABLE 212 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
TABLE 213 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 214 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 215 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 216 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 USD MILLION)
TABLE 217 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
10 RECOMBINANT PROTEINS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 218 RECOMBINANT PROTEINS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: RECOMBINANT PROTEINS MARKET SNAPSHOT
TABLE 219 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 220 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 221 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 222 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 223 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 224 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 225 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 USD MILLION)
TABLE 226 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 Rising investments in life sciences research to drive market
TABLE 227 US: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 228 US: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 229 US: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 230 US: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 231 US: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 232 US: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 233 US: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 High incidence of cancer and favorable healthcare investments to drive market
TABLE 234 CANADA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 235 CANADA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 236 CANADA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 237 CANADA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 238 CANADA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 239 CANADA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 240 CANADA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3 EUROPE
TABLE 241 EUROPE: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 242 EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 243 EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 244 EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 245 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 246 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 247 EUROPE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 248 EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Growing focus on biotech clusters to drive market
TABLE 249 GERMANY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 250 GERMANY: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 251 GERMANY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 252 GERMANY: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 253 GERMANY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 254 GERMANY: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 255 GERMANY: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Rising demand for biologics and biosimilars to propel market
TABLE 256 UK: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 257 UK: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 258 UK: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 259 UK: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 260 UK: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 261 UK: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 262 UK: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Rising establishment of biopharmaceutical production facilities to boost demand
TABLE 263 FRANCE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 264 FRANCE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 265 FRANCE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 266 FRANCE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 267 FRANCE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 268 FRANCE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 269 FRANCE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Growth in proteomics and genomics research to drive market
TABLE 270 ITALY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 271 ITALY: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 272 ITALY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 273 ITALY: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 274 ITALY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 275 ITALY: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 276 ITALY: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Rising establishment of pharmaceutical production facilities to drive market
TABLE 277 SPAIN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 278 SPAIN: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 279 SPAIN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 280 SPAIN: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 281 SPAIN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 282 SPAIN: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 283 SPAIN: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 284 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 285 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 286 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 287 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 288 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 289 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 290 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET SNAPSHOT
TABLE 291 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 292 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 293 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 294 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 295 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH APPLICATION, BY TYPE, 2021–2028 (USD MILLION)
TABLE 296 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2021–2028 (USD MILLION)
TABLE 297 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 298 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Expansion of R&D infrastructure to support market growth
TABLE 299 CHINA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 300 CHINA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 301 CHINA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 302 CHINA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 303 CHINA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 304 CHINA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 305 CHINA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Growth in pharmaceutical industry to propel market
TABLE 306 JAPAN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 307 JAPAN: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 308 JAPAN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 309 JAPAN: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 310 JAPAN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 311 JAPAN: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 312 JAPAN: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Rising demand for drug discovery & development to propel market
TABLE 313 INDIA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 314 INDIA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 315 INDIA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 316 INDIA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 317 INDIA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 318 INDIA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 319 INDIA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Rising incidence of infectious diseases to drive market
TABLE 320 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 321 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 322 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 323 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 324 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 325 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 326 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 327 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 328 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 329 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 330 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 331 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 332 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 333 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5 LATIN AMERICA
TABLE 334 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 335 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 336 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 337 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 338 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 339 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 340 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 341 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 Rising incidence of chronic diseases to drive market
TABLE 342 BRAZIL: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 343 BRAZIL: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 344 BRAZIL: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 345 BRAZIL: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 346 BRAZIL: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 347 BRAZIL: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 348 BRAZIL: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 349 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 350 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 351 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 352 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 353 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 354 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 355 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6 MIDDLE EAST
TABLE 356 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 357 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 358 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 359 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 360 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 361 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 362 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 363 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6.1 MIDDLE EAST: RECESSION IMPACT
10.6.2 GCC COUNTRIES
10.6.2.1 Rising government investments in healthcare to support market growth
TABLE 364 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 365 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 366 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 367 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 368 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 369 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 370 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.6.3 REST OF THE MIDDLE EAST
TABLE 371 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 372 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 373 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 374 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 375 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 376 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 377 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.7 AFRICA
10.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
TABLE 378 AFRICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 379 AFRICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 380 AFRICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 381 AFRICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
TABLE 382 AFRICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION)
TABLE 383 AFRICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION)
TABLE 384 AFRICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.7.2 AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES
FIGURE 32 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN
11.3 REVENUE SHARE ANALYSIS
FIGURE 33 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020?2022)
11.4 MARKET SHARE ANALYSIS
FIGURE 34 RECOMBINANT PROTEINS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
TABLE 385 RECOMBINANT PROTEINS MARKET: INTENSITY OF COMPETITIVE RIVALRY
11.5 COMPANY EVALUATION MATRIX
FIGURE 35 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPETITIVE BENCHMARKING
11.5.5.1 Product footprint (15 companies)
TABLE 386 RECOMBINANT PROTEINS MARKET: COMPANY PRODUCT FOOTPRINT
11.5.5.2 Regional footprint
TABLE 387 RECOMBINANT PROTEINS MARKET: REGIONAL FOOTPRINT ANALYSIS
11.6 START-UP/SME EVALUATION MATRIX
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 36 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022)
11.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES
TABLE 388 RECOMBINANT PROTEINS MARKET: PRODUCT FOOTPRINT
TABLE 389 RECOMBINANT PROTEINS MARKET: REGIONAL FOOTPRINT
11.7 COMPETITIVE SCENARIO
11.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 390 RECOMBINANT PROTEINS MARKET: PRODUCT LAUNCHES & APPROVALS, (JANUARY 2021–SEPTEMBER 2023)
11.7.2 DEALS
TABLE 391 RECOMBINANT PROTEINS MARKET: DEALS (JANUARY 2021?SEPTEMBER 2023)
11.7.3 OTHER DEVELOPMENTS
TABLE 392 RECOMBINANT PROTEINS MARKET: OTHER DEVELOPMENTS (JANUARY 2021?SEPTEMBER 2023)
12 COMPANY PROFILES
(Business overview, Products offered, Recent developments & MnM View)*
12.1 KEY PLAYERS
12.1.1 BIO-TECHNE
TABLE 393 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 37 BIO?TECHNE: COMPANY SNAPSHOT (2022)
TABLE 394 BIO?TECHNE: PRODUCTS OFFERED
TABLE 395 BIO-TECHNE: DEALS
TABLE 396 BIO-TECHNE: OTHER DEVELOPMENTS
12.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 397 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
TABLE 398 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 399 THERMO FISHER SCIENTIFIC INC: DEALS
12.1.3 MERCK KGAA
TABLE 400 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2022)
TABLE 401 MERCK KGAA: PRODUCTS OFFERED
TABLE 402 MERCK KGAA: DEALS
TABLE 403 MERCK KGAA: OTHER DEVELOPMENTS
12.1.4 ABCAM PLC
TABLE 404 ABCAM PLC: BUSINESS OVERVIEW
FIGURE 40 ABCAM PLC: COMPANY SNAPSHOT (2022)
TABLE 405 ABCAM PLC: PRODUCTS OFFERED
TABLE 406 ABCAM PLC: DEALS
TABLE 407 ABCAM PLC: OTHER DEVELOPMENTS
12.1.5 ABNOVA CORPORATION
TABLE 408 ABNOVA CORPORATION: BUSINESS OVERVIEW
TABLE 409 ABNOVA CORPORATION: PRODUCTS OFFERED
12.1.6 BIOLEGEND, INC
TABLE 410 BIOLEGEND INC: BUSINESS OVERVIEW
TABLE 411 BIOLEGEND INC: PRODUCTS OFFERED
12.1.7 BIO-RAD LABORATORIES, INC.
TABLE 412 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 41 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
TABLE 413 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
12.1.8 BPS BIOSCIENCE, INC.
TABLE 414 BPS BIOSCIENCE, INC.: BUSINESS OVERVIEW
TABLE 415 BPS BIOSCIENCE, INC.: PRODUCTS OFFERED
12.1.9 ENZO LIFE SCIENCES, INC. (SUBSIDIARY OF ENZO BIOCHEM, INC.)
TABLE 416 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
FIGURE 42 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022)
TABLE 417 ENZO BIOCHEM, INC.: PRODUCTS OFFERED
TABLE 418 ENZO BIOCHEM, INC.: OTHER DEVELOPMENTS
12.1.10 GENSCRIPT
TABLE 419 GENSCRIPT: BUSINESS OVERVIEW
FIGURE 43 GENSCRIPT: COMPANY SNAPSHOT (2022)
TABLE 420 GENSCRIPT: PRODUCTS OFFERED
12.1.11 MILTENYI BIOTEC B.V. & CO. KG
TABLE 421 MILTENYI BIOTEC B.V. & CO. KG: BUSINESS OVERVIEW
TABLE 422 MILTENYI BIOTEC B.V. & CO. KG: PRODUCTS OFFERED
TABLE 423 MILTENYI BIOTEC B.V. & CO. KG: PRODUCT LAUNCHES
12.1.12 PROTEINTECH GROUP, INC.
TABLE 424 PROTEINTECH GROUP, INC.: BUSINESS OVERVIEW
TABLE 425 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED
TABLE 426 PROTEINTECH GROUP, INC.: DEALS
TABLE 427 PROTEINTECH GROUP, INC.: OTHER DEVELOPMENTS
12.1.13 SINO BIOLOGICAL, INC.
TABLE 428 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
TABLE 429 SINO BIOLOGICAL, INC.: PRODUCTS OFFERED
TABLE 430 SINO BIOLOGICAL, INC.: PRODUCT LAUNCHES
TABLE 431 SINO BIOLOGICAL, INC.: DEALS
TABLE 432 SINO BIOLOGICAL, INC.: OTHER DEVELOPMENTS
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 ACROBIOSYSTEMS GROUP
12.2.2 AVIVA SYSTEMS BIOLOGY CORPORATION
12.2.3 SARTORIUS CELLGENIX GMBH
12.2.4 ICOSAGEN
12.2.5 NEUROMICS
12.2.6 PROSPEC-TANY TECHNOGENE LTD.
12.2.7 PROTEOGENIX S.A.S
12.2.8 RAYBIOTECH, INC.
12.2.9 LAURUS BIO
12.2.10 STEMCELL TECHNOLOGIES
12.2.11 STRESSMARQ BIOSCIENCES INC.
12.2.12 UNITED STATES BIOLOGICAL
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
